BridgeBio Pharma Inc (BBIO)
BridgeBio Pharma Inc (NASDAQ-BBIO) is a biotechnology company whose common stock trades on the NASDAQ exchange. The company’s work is centered on therapies for genetic and other serious medical conditions, with research and development spanning multiple disease areas. As a common equity security, BBIO represents an ownership interest in BridgeBio Pharma Inc rather than a fund, debt instrument, or other security type. The shares are listed in the healthcare sector and biotechnology industry, and the security context is common equity. This overview describes the listed stock and the company behind it in broad terms without making claims about performance or prospects.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BBIO
|
$78.27
|
-3.7% Downside
|
Fair
|
$105.26
|
29.4% Upside
|
Undervalued
|
Good
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-22.1x
|
-7.0x
|
27.5x
|
15.832 B
|
17.521 B
|
13.6%
|
84.1%
|
-2.0
|
—
|
61.7%
|
